Abbott, Astellas Using m2000 to Test Patient Viral Load in CMV Vaccine Trial | GenomeWeb

Abbott said today that has signed an agreement to collaborate with Astellas Pharma Global Development in a phase III clinical trial for Astellas' investigational vaccine to prevent cytomegalovirus reactivation in transplant patients.

Under the agreement, researchers from the companies will use Abbott's RealTime CMV assay on the m2000 System to monitor patients for CMV viral load in order to assess the efficacy of the vaccine, called ASP0113, or TransVax.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."